Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

25.91 -0.18 (-0.69%)
Streaming Delayed Price Updated: 11:13 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Protagonist Therapeutics Inc

< Previous 1 2 Next >
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Via ACCESSWIRE
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
Via ACCESSWIRE
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
Via ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
Via ACCESSWIRE
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
Via ACCESSWIRE
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
Via ACCESSWIRE
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
Via ACCESSWIRE
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
Via ACCESSWIRE
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
Via ACCESSWIRE
Protagonist Receives $34 Million from Warrant Exercises
Via ACCESSWIRE
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
Via ACCESSWIRE
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
Via ACCESSWIRE
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
Via ACCESSWIRE
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
Via ACCESSWIRE
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
Via ACCESSWIRE
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
Via ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
Via ACCESSWIRE
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
Via FinancialNewsMedia
Protagonist Therapeutics to Present at Upcoming Investor Conferences
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.